Analyst Salveen Richter of Goldman Sachs maintained a Hold rating on Gilead Sciences (GILD – Research Report), with a price target of ...

(Nasdaq: GILD) announced today its first quarter 2024 results of operations. "Gilead delivered another strong quarter of ...

Emily Field, an analyst from Barclays, maintained the Hold rating on Gilead Sciences (GILD – Research Report). The associated price ...

Cidara is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel anti-infectives. The firm is applying its proprietary Cloudbreak platform to ...